Midkine confers Adriamycin resistance in human gastric cancer cells

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1543-1548

  Xu, Ying Ying ^a   Mao, Xiao Yun ^a   Song, Yong Xi ^a   Zhao, Feng ^a   Wang, Zhen Ning ^a   Zhang, Wei Xu ^a   Xu, Hui Mian ^a   Jin, Feng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Adriamycin resistance; Gastric cancer; Midkine

Indexed keywords

DOXORUBICIN; MIDKINE; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; UPREGULATION;

EID: 84868135098     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0406-3     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Grémy G, Couillault C, Lajémi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S. Deciphering cellular states of innate tumor drug responses. Genome Biol. 2006;7(3):R19.
3. Kerzerho J, Adotevi O, Castelli FA, Dosset M, Bernardeau K, Szely N, Lang F, Tartour E, Maillere B. The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol. 2010;185:418-23.
4. Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86:410-25.
5. Zhao ZQ, Yang S, Lu HS. Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Mol Med Report. 2012;5:415-9.
6. Grzelinski M, Steinberg F, Martens T, Czubayko F, Lamszus K, Aigner A. Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia. 2009;11:145-56.
7. Xu Y, Qu X, Zhang X, Luo Y, Zhang Y, Luo Y, Hou K, Liu Y. Midkine positively regulates the proliferation of human gastric cancer cells. Cancer Lett. 2009;279:137-44.
8. Du WW, Yang BB, Yang BL, Deng Z, Fang L, Shan SW, Jeyapalan Z, Zhang Y, Seth A, Yee AJ. Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy. PLoS One. 2011;6:e26396.
9. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem. 2002;132:359-71.
10. Ota K, Fujimori H, Ueda M, Shiniriki S, Kudo M, Jono H, Fukuyoshi Y, Yamamoto Y, Sugiuchi H, Iwase H, Shinohara M, Ando Y. Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer. 2008;99:655-62.
11. Yokota K, Hirano T, Urata N, Yamauchi N, Hattori MA. Upregulation of P-glycoprotein activity in porcine oocytes and granulosa cells during in vitro maturation. J Reprod Dev. 2011;57:322-6.
12. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263-84.
13. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005;117:376-80.
14. Tong Y, Mentlein R, Buhl R, Hugo HH, Krause J, Mehdorn HM, Held-Feindt J. Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas. J Neurochem. 2007;100:1097-107.
15. Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T, Michikawa M. Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem. 1999;73:2084-92.
16. Sandra F, Harada H, Nakamura N, Ohishi M. Midkine induced growth of ameloblastoma through MAPK and Akt pathways. Oral Oncol. 2004;40:274-80.
17. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277:35990-8.
18. Dai LC, Wang X, Yao X, Min LS, Ping JL, He JF. Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model. Acta Pharmacol Sin. 2007;28:453-8.
19. Dai LC, Yao X, Wang X, Niu SQ, Zhou LF, Fu FF, Yang SX, Ping JL. In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles. World J Gastroenterol. 2009;15:1966-72.
20. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 2011;10:3003-15.
21. Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget. 2011;2:538-50.